FIG 4.

Prophylactic PG545 application protects mice against genital infection. PG545 was administered intravaginally to mice ∼10 min prior to or after infection with HSV-2, and animals were monitored for survival rates (A), disease scores (B), viral DNA (C), and infectious virus (D) in vaginal lavage fluids sampled at day 3 postinfection. Fisher's exact test was used to analyze survival data in panel A. ANOVA was used to analyze the data in panels C and D, and the horizontal bars indicate median values of each group. Asterisks indicate significant difference as follows: *, P < 0.05, and **, P < 0.01.